BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26882224)

  • 21. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
    Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
    Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
    Su K; Zhang T; Wang Y; Hao G
    World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer.
    Shen J; Todd NW; Zhang H; Yu L; Lingxiao X; Mei Y; Guarnera M; Liao J; Chou A; Lu CL; Jiang Z; Fang H; Katz RL; Jiang F
    Lab Invest; 2011 Apr; 91(4):579-87. PubMed ID: 21116241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
    Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
    Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of long non-coding RNA HOTTIP in early-stage non-small-cell lung cancer.
    Navarro A; Moises J; Santasusagna S; Marrades RM; Viñolas N; Castellano JJ; Canals J; Muñoz C; Ramírez J; Molins L; Monzo M
    BMC Pulm Med; 2019 Feb; 19(1):55. PubMed ID: 30819158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    Wang JZ; Xiang JJ; Wu LG; Bai YS; Chen ZW; Yin XQ; Wang Q; Guo WH; Peng Y; Guo H; Xu P
    BMC Cancer; 2017 Mar; 17(1):167. PubMed ID: 28253859
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
    Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
    Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of the factors associated with abnormal coagulation and prognosis
 in patients with non-small cell lung cancer].
    Li Y; Wei S; Wang J; Hong L; Cui L; Wang C
    Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):789-96. PubMed ID: 25404269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
    Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
    Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
    Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
    Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
    Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
    Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.
    Vlachostergios PJ; Oikonomou KG; Gibilaro E; Apergis G
    Cancer Biomark; 2015; 15(6):725-34. PubMed ID: 26406401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study.
    Trovo M; Giaj-Levra N; Furlan C; Bortolin MT; Muraro E; Polesel J; Minatel E; Tedeschi R; Filippi AR; Alongi F; Ricardi U
    Clin Transl Oncol; 2016 Oct; 18(10):1003-10. PubMed ID: 26687367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.